Real-world evidence

Caporusso et al case series¹

In real-world patients (retrospective case series), NuShield^® was used in a wide variety of wounds (N=50), including VLUs (n=14), DFUs (n=24), and other wounds (pressure ulcers, nonhealing surgical, ischemic, mixed etiology, and nonhealing amputation; n=12).¹

Median time to wound closure¹

Estimated median time to complete wound closure for wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata: P=0.071 (Wilcoxon). ^*All wounds includes DFUs, VLUs, and other wounds. ^†Other includes 3 pressure injuries; 4 nonhealing surgical, 1 ischemic, and 1 mixed etiology wound; 1 nonhealing amputation; and 1 not identified.¹

Percentage of wounds closed by week¹

Estimated frequency of complete wound closure for wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata: P=0.071 (Wilcoxon). ^*All wounds includes DFUs, VLUs, and other wounds. ^†Other includes 3 pressure injuries; 4 nonhealing surgical, 1 ischemic, and 1 mixed etiology wound; 1 nonhealing amputation; and 1 not identified.¹

Of those wounds that did not achieve wound closure, 9 (18%) had >90% wound closure, and 8 (16%) had wound closures ranging from 60% to 90% by the last observation.¹